This study uncovers a novel mechanism by which Alu element-mediated genomic rearrangements trigger neurodegeneration through disruption of the ZnT6–Golgi axis, providing a direct experimental paradigm for disease modeling and intervention strategies in Alzheimer’s disease and hereditary spastic paraplegia.
Literature Overview
The study titled “Alu-mediated SPAST deletion impairs golgi zinc transport and reveals a druggable vulnerability,” published in Signal Transduction and Targeted Therapy, systematically investigates how Alu element-mediated deletion of SPAST exon 17 generates a SPAST–SLC30A6 fusion transcript, leading to downregulation of ZnT6 expression, zinc dyshomeostasis, Golgi fragmentation, and ultimately neurodegenerative pathology. By integrating human pluripotent stem cell-derived cortical organoids and xenotransplantation models, the study reveals a conserved pathogenic cascade from genomic structural variation to organelle dysfunction. Notably, this mechanism is partially recapitulated in brain tissues from sporadic Alzheimer’s disease patients, suggesting its broader relevance.Background Knowledge
Neurodegenerative disorders such as Alzheimer’s disease (AD) and hereditary spastic paraplegia (HSP) exhibit significant clinical and pathological overlap. Patients with large SPAST deletions often present cognitive decline and dementia, yet the underlying molecular mechanisms remain unclear. SPAST encodes the microtubule-severing protein spastin; point mutations typically cause pure motor phenotypes, whereas large deletions are more frequently associated with cognitive impairment, suggesting additional pathogenic mechanisms. The SPAST locus is enriched with Alu elements, particularly in intron 16 and exon 17, which are prone to mediate non-allelic homologous recombination, resulting in structural variants. However, traditional animal models such as mice lack Alu elements, making it difficult to recapitulate such primate-specific genomic instability, creating a research bottleneck. This study leverages human organoid models to investigate whether Alu-mediated SPAST deletions disrupt downstream gene SLC30A6 (encoding ZnT6), leading to zinc transport defects and linking genomic variation to neuronal homeostasis disruption.
Research Methods and Experiments
The authors used CRISPR/Cas9 to engineer human pluripotent stem cells (hPSCs) with a deletion of SPAST exon 17, mimicking Alu-mediated genomic rearrangements, and differentiated them into cortical organoids (COs) to model human neurodevelopment. Using whole transcriptome sequencing, single-cell RNA-seq, western blotting, and immunofluorescence, they systematically analyzed molecular and cellular phenotypes in the mutant organoids. To further simulate the in vivo environment, the organoids were transplanted into the brains of immunodeficient mice to establish a xenotransplantation model, allowing assessment of pathology progression in a more complex microenvironment. Additionally, the study examined ZnT6 expression and Golgi status in brain tissues from Alzheimer’s disease patients and screened for the presence of SPAST–SLC30A6 fusion transcripts to validate the conservation of the mechanism.Key Conclusions and Perspectives
Research Significance and Prospects
This study is the first to directly link primate-specific Alu element-mediated structural variation with zinc dyshomeostasis and Golgi dysfunction, proposing a novel pathogenic pathway. It provides new insights into the mechanisms underlying dementia in HSP and suggests ZnT6 as a potential therapeutic target. Future efforts could focus on developing small-molecule compounds that enhance ZnT6 function or stabilize the Golgi apparatus to explore their intervention potential in multiple neurodegenerative diseases.
From a clinical monitoring perspective, p-GM130, as a marker of Golgi fragmentation, may more stably reflect neuronal stress states than ZnT6 expression, warranting further investigation into its detectability in cerebrospinal fluid or exosomes. Moreover, the preliminary evidence of this mechanism in sporadic AD suggests expanding cohort screening for SPAST–SLC30A6 fusion events to assess their value as molecular biomarkers for AD subtypes.
In terms of disease modeling, this study highlights the unique advantages of human organoids combined with xenotransplantation in modeling human-specific genomic instability and neuropathology, particularly for diseases driven by repetitive elements such as Alu. This model could be used in future high-throughput drug screens to identify candidate molecules that restore Golgi structure or regulate zinc distribution.
Conclusion
This study, by integrating organoid and xenotransplantation models, reveals a novel mechanism whereby Alu-mediated SPAST deletion downregulates ZnT6 via a SPAST–SLC30A6 fusion transcript, disrupting zinc transport and Golgi integrity, thereby driving neurodegeneration. This finding not only explains why large SPAST deletions are more likely to cause cognitive impairment but also identifies zinc homeostasis and Golgi dysfunction as druggable vulnerabilities, linking structural variation to neuronal death. More importantly, the detection of the same fusion transcript in sporadic Alzheimer’s disease patients suggests that this mechanism may transcend traditional disease classifications, defining a new neurodegenerative subtype. From bench to bedside, this discovery provides a theoretical foundation for developing interventions targeting the ZnT6–Golgi axis and offers critical molecular clues for future precision subtyping and targeted therapies, potentially reshaping our understanding of neurodegenerative disease mechanisms and treatment strategies.
